The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™.
Amicus Therapeutics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $13.33 and fluctuated between $13.35 as its day high and $12.99 as its day low. The current market capitalization of Amicus Therapeutics Inc is $3.91B. A total of 1.6 million shares were traded on the day, compared to an average of 3.05M shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, FOLD has seen 0 BUY and 1 SELL insider trades, representing the acquisition of 0 and the disposition of 6,043 shares. Over the last 12 months, there were 25 BUYs and 40 SELLs from insiders. Insiders purchased 347,854 shares during that period but sold 336,412.
In the most recent transaction, Rosenberg Ellen sold 29,600 shares of FOLD for 13.00 per share on Feb 07. After the transaction, the Chief Legal Officer now owns 367,654 company shares. In a previous transaction on Feb 06, Rosenberg Ellen sold 400 shares at 13.00 per share. FOLD shares that Chief Legal Officer owns now total 367,654.
Among the insiders who sold shares, Crowley John F disposed of 31,614 shares on Feb 01 at a per-share price of $12.62. This resulted in the Executive Chairman holding 750,838 shares of FOLD after the transaction. In another insider transaction, Campbell Bradley L sold 15,833 shares at $12.56 per share on Feb 01. Company shares held by the President and CEO now total 875,386.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for FOLD in the last 3 months, the mean price target is $19.56 with high estimates of $22.00 and low estimates of $16.00. In terms of 52-week highs and lows, FOLD has a high of $14.57 and a low of $9.70.
As of this writing, FOLD has an earnings estimate of -$0.06 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of -$0.01 per share and a lower estimate of -$0.1. The company reported an EPS of -$0.15 in the last quarter, which was -25.00% lower than expectations of -$0.12.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. FOLD’s latest balance sheet shows that the firm has $482.50M in Cash & Short Term Investments as of fiscal 2021. There were $440.13M in debt and $145.97M in liabilities at the time. Its Book Value Per Share was $0.46, while its Total Shareholder’s Equity was $307.37M.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for FOLD is Buy with a score of 4.60.